Evaluation of Wnt5a and LRP5 Levels in Serum and Saliva Samples and the Relationship Between Clinical Periodontal Parameters

Expression of Wnt5a and WNT Coreceptor (LRP5) Levels in Stage III Periodontitis Patients

Objectives: Wnt5a is a secreted Wnt ligand that plays an important role in cellular homeostasis. Wnt interaction with coreceptor low-density lipoprotein receptor-related protein 5 (LRP5) induces the proliferation of osteoblasts and prolongs their functional life. The aim of this study is evaluating the levels of Wnt5a and LRP5 in serum and saliva samples and relationship between clinical periodontal parameters.

Method: Saliva and serum samples were collected from 20 systemically healthy patients with stage III periodontitis and 20 periodontally healthy controls. Wnt5a and LRP5 levels were measured using enzyme-linked immunosorbent assay (ELISA). Clinical periodontal parameters including plaque index (PI), probing pocket depth (PPD), bleeding on probing (BOP), and clinical attachment level (CAL) were recorded.

Inclusion Criteria:

• >18 years old,
• At least 16 permanent teeth except 3rd molars,
• Individuals who do not use orthodontic appliances,
• Individuals who are not pregnant or lactating,
• Individuals without any systemic disease that may affect periodontal health,
• Systemically healthy individuals,
• Individuals who have not used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
• Individuals who have not received periodontal treatment in the last 1 year

Exclusion Criteria:

• Pregnant/lactating individuals,
• Individuals who have used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
• Individuals who have undergone periodontal treatment in the last 1 year,
• Individuals with psychiatric illness,
• Individuals with any oral infection,
• Individuals with <16 teeth, excluding molars,
• Individuals with alcohol dependence,
• Individuals with active infectious disease (acute hepatitis, AIDS, tuberculosis), cancer or any systemic condition that may affect periodontal tissues,
• Individuals receiving treatment with drugs known to affect periodontal tissues (phenytoin, cyclosporine A, calcium channel blockers)